Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline to Registration

Ads

You May Also Like

CrownBio推出新型人源化免疫療法標靶模型

聖地牙哥, May 04, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience是Crown Bioscience International (TWSE:6554) 的全資附屬公司,亦是一家全球藥物發現和開發服務公司,為促進腫瘤、炎症、心血管和代謝疾病研究提供轉化平台,透過推出一種新型轉基因CD3E模型以促進免疫腫瘤(I/O  /  ...